论文信息 - Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report - 字舞流文

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

E. Walsh | A. Falsey | P. Dormitzer | M. Mulligan | N. Kitchin | J. Absalon | A. Gurtman | S. Lockhart | R. Bailey | K. Swanson | K. Koury | Ping Li | W. Kalina | D. Cooper | R. Frenck | U. Şahin | K. Jansen | W. Gruber | K. Neuzil | P. Shi | K. Lyke | V. Raabe | C. Fontes-Garfias | Ӧzlem Türeci | Kristin Tompkins | Camila R. Fontes-Garfias | David Cooper